Huangpu Biopharmaceutical Fund

Huangpu Biopharmaceutical Fund is a specialized venture capital and private equity firm based in Guangzhou, China, focused on the life sciences and healthcare sectors. Established in 2019, the fund is a collaborative initiative sponsored by the Guangzhou Development District Holding Group, Force Capital, BeiGene, and Guojv Venture Capital. It leverages the research and development expertise of BeiGene to identify and support high-potential biotechnology and medical device projects, particularly within the Guangdong-Hong Kong-Macao Greater Bay Area. The fund's investment strategy covers innovative drug development, synthetic biology, and advanced medical technologies, with a portfolio that includes leaders in protein degradation, siRNA delivery, and antibody therapies.